Strategies for HPV prevention

Virus Research

Volumn 89, Issue 2, 2002, Pages 285-293

  Plummer, Martyn ^a   Franceschi, Silvia ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Projections; Randomized trials; Vaccination

Indexed keywords

PROTEIN L1; PROTEIN L2; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CLINICAL TRIAL; CONDOM; CONFERENCE PAPER; CYTODIAGNOSIS; DEVELOPING COUNTRY; DRUG EFFICACY; EXPERIMENTAL DESIGN; HEALTH PROGRAM; HUMAN; INDIA; INFECTION CONTROL; INFECTION PREVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; SCREENING TEST; SEXUAL TRANSMISSION; SOUTH KOREA; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RANDOMIZED CONTROLLED TRIALS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0036848779     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(02)00197-1     Document Type: Conference Paper

References (43)

1. Beral V., Hermon C., Muñoz N., Devesa S.S. Cervical cancer. Cancer Surv. 19/20:1994;265-285.
2. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:1995;796-802.
3. Brinton L.A., Reeves W.C., Brenes M.M., Herrero R., Gaitan E., Tenorio F., de Britton R.C., Garcia M., Rawls W.E. The male factor in the etiology of cervical cancer among sexually monogamous women. Int. J. Cancer. 44:1989;199-203.
4. Castellsagué X., Bosch F.X., Muñoz N., Meijer C., Shah K., de Sanjosé S., Eluf-Neto J., Ngelangel C.A., Chichareon S., Smith J.S., Herrero R., Franceschi S. Male circumcision, penile human papillomavirus infection and cervical cancer in female partners. New Engl. J. Med. 346:2002;1105-1112.
5. Celentano D.D., Klassen A.C., Weisman C.S., Rosenshein N.B. The role of contraceptive use in cervical cancer: the Maryland cervical cancer case-control study. Am. J. Epidemiol. 126:1987;592-604.
6. Clifford, G.M., Smith, J.S., Plummer, M., Muñoz, N., Franceschi, S., 2002. Human Papillomaviruses in Invasive Cervical Cancer Worldwide: A Meta-analysis, submitted for publication.
7. Coleman M.P., Esteve J., Damiecki P., Arslan A., Renard H. Trends in Cancer Incidence and Mortality. IARC Scientific Publications No 121. 1993;International Agency for Research on Cancer, Lyon.
8. Ferlay, J., Bray, F., Pisani, P., Parkin, D.M., 2001. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5, IARC Press, Lyon.
9. Franceschi S. Strategies to reduce the risk of virus-related cancers. Ann. Oncol. 11:2000;1091-1096.
10. Franceschi S., Castellsagué X., Dal Maso L., Smith J.S., Plummer M., Ngelangel C., Chichareon S., Eluf-Neto J., Shah K.V., Snijders P.J.F., Meijer C.J.L.M., Bosch F.X., Muñoz N. Prevalence and determinants of human papillomavirus genital infection in men. Br. J. Cancer. 86:2002;705-711.
11. Gambia Hepatitis Study Group . Cancer Res. 47:1987;5782-5787.
12. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., Mast T.C., Robinson R., Murphy B.R., Karron R.A., Dillner J., Schiller J.T., Lowy D.R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 21:2001;284-292.
13. Hermonat P.L., Daniel R.W., Shah K. Nonoxynol-9 does not inactivate papillomavirus. Sex. Transmission Dis. 19:1992;203-205.
14. Hildesheim A., Brinton L., Mallin K., Lehman H.F., Stolley P., Savitz D., Levine R. Barrier and spermicidal contraceptive methods and risk of invasive cervical cancer. Epidemiology. 1:1990;262-266.
15. Huang K., Lin S. Nationwide vaccination: a success story in Taiwan. Vaccine. 18:(Suppl. 1):2000;S35-S38.
16. IARC, 1994. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Hepatitis Viruses, vol. 59, International Agency for Research on Cancer, Lyon.
17. IARC, 1995. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses, vol. 64, International Agency for Research on Cancer, Lyon.
18. Kols, A., Sherris, J., 2000. HPV Vaccines: Promise and Challenges. PATH, Seattle, WA.
19. Krüger Kjaer S., van den Brule A.J., Bock J.E., Poll P.A., Engholm G., Sherman M.E., Walboomers J.M., Meijer C.J. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types. Cancer Epidemiol. Biomark. Prev. 6:1997;799-805.
20. Lazcano-Ponce E., Herrero R., Munoz N., Cruz A., Shah K.V., Alonso P., Hernandez P., Salmeron J., Hernandez M. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int. J. Cancer. 91:2001;412-420.
21. Li H., Jin S., Xu H., Thomas D.B. The decline in the mortality rates of cervical cancer and a plausible explanation in Shandong, China. Int. J. Epidemiol. 29:2000;398-404.
22. Molano M., Posso H., Weiderpass E., van den Brule A.J.C., Ronderos M., Franceschi S., Meijer C.J.L.M., Arslan A., Muñoz N. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br. J. Cancer. 87:2002;324-333.
23. Moreno V., Bosch F.X., Munoz N., Meijer C.J., Shah K.V., Walboomers J.M., Herrero R., Franceschi S. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 359:2002;1085-1192.
24. Munoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S., Shah K.V., Meijer C.J., Bosch F.X. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 359:2002;1093-1101.
25. Parazzini F., Negri E., La Vecchia C., Fedele L. Barrier methods of contraception and the risk of cervical neoplasia. Contraception. 40:1989;519-540.
26. Parkin, D.M., Whelan, S.L., Ferlay, J., Raymond, L., Young, J., 1997. Cancer incidence in five continents, Vol VII. IARC scientific publications No 143. International Agency for Research on Cancer, Lyon.
27. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer. 80:1999;827-841.
28. Pisani P., Parkin D.M., Bray F., Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer. 83:1999;18-29.
29. Plummer, M., Herrero, R., Franceschi, S., Meijer, C.J.L.M., Snijders, P., Bosch, F.X., de Sanjosé, S., Muñoz, N. Smoking and Cervical Cancer: Pooled Analysis of a Multicentric Case-control Study. Submitted.
30. Sankaranarayanan R., Wesley R., Somanathan T., Dhakad N., Shyamalakumary B., Amma N.S., Parkin D.M., Nair M.K. Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. Cancer. 83:1998;2150-2156.
31. Sankaranarayanan R., Budukh A.M., Rajkumar R. Effective screening programs for cervical cancer in low- and middle-income developing countries. Bull. World Health Organ. 79:2001;954-962.
32. Sasieni P., Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. Br. Med. J. 318:1999;1244-1245.
33. Sasieni P., Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet. 357:2001;1490-1493.
34. Sherris J., Herdman C. Preventing cervical cancer in low-resource settings. Outlook. 18:2000;1-8.
35. Smith, J.S., Muñoz, N., Bosetti, C., Herrero, R., Bosch, F.X., Eluf-Neto, J., van den Brule, A., Franceschi, S., Peeling, R., 2001. Chlamydia trachomatis as an HPV cofactor in the etiology of invasive cervical cancer: A pooled analysis of seven countries. Nineteenth International Papillomavirus Conference, O-135.
36. Smith, J.S., Herrero, R., Bosetti, C., Muñoz, N., Bosch, F.X., Eluf-Neto, J., Castellsagué, X., Meijer, C.J.L.M., Van den Brule, A., Franceschi, S., Ashley, R., 2002. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst., in press.
37. Sukrivach, S., Smith, J.S., Kesararat, W., Kaenploy, V., Meijer, C.J.L.M., Snijders, P., Franceschi, S., Herrero, R., 2001. Population-based human papilloma virus prevalence in Lampang and Songkla, Thailand. Nineteenth International Papillomavirus Conference, P-243.
38. Viviani S., Jack A., Hall A.J., Maine N., Mendy M., Montesano R., Whittle H.C. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine. 17:1999;2946-2950.
39. Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Parkin D.M. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int. J. Cancer. 75:1998;536-545.
40. Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Borras J., Parkin D.M. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J. Cancer. 86:2000;429-435.
41. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 18:1999;12-19.
42. Wesley R., Sankaranarayanan R., Mathew B., Chandralekha B., Aysha Beegum A., Amma N.S., Nair M.K. Evaluation of visual inspection as a screening test for cervical cancer. Br. J. Cancer. 75:1997;436-440.
43. Wright N.H., Vessey M.P., Kenward B., McPherson K., Doll R. Neoplasia and dysplasia of the cervix uteri and contraception: a possible protective effect of the diaphragm. Br. J. Cancer. 38:1978;273-279.